Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multi-arm immunotherapy study in MSI-high metastatic colorectal cancer
NL-OMON58894Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- May 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of quavonlimab, pembrolizumab, favezelimab, vibostolimab and mk-4830 in colorectal cancer (CRC) (7 cohorts), sponsored by Merck & Co. Primary endpoint: Objective Response Rate. Started May 2023; status: completed.
02
Drugs
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NL-OMON58894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58894.